ASX-LISTED clinical trials firm Proteomics International has announced a new strategic alliance with CPR Pharma Services, with a share swap deal which will see Proteomics acquire 10% of CPR.
The combined companies will offer a "unique R&D focused Contract Research Organisation capability" with project management, certified bioanalysis, trial monitoring, statistics and data management and development of new methods and diagnostic tests.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Feb 18
